Succinylcholine drug interactions during electroconvulsive therapy

Area of Science:

• Anesthesiology
• Pharmacology
• Psychiatry

Background:

• Electroconvulsive therapy (ECT) is generally considered safe with minimal absolute contraindications.
• Succinylcholine, a common muscle relaxant used in ECT, possesses acetylcholine-like effects beyond neuromuscular blockade.
• An aging population undergoing chemotherapy may increasingly require ECT, raising concerns about drug interactions.

Purpose of the Study:

• To highlight potential hazards associated with drug interactions involving succinylcholine during ECT.
• To inform clinicians about specific drug classes that interact with succinylcholine.
• To provide guidance on managing these interactions and their complications.

Main Methods:

• Review of literature on drug interactions with succinylcholine in the context of ECT.
• Identification of drugs affecting cholinesterase activity, acetylcholine release, or synthesis.
• Analysis of psychotropic medications known to interact with succinylcholine.

Main Results:

• Drugs inhibiting cholinesterase or acetylcholine synthesis/release can cause prolonged respiratory paralysis with succinylcholine.
• Certain psychotropic medications present significant risks when combined with succinylcholine.
• The risk of adverse interactions is increasing due to patient demographics and polypharmacy.

Conclusions:

• Clinicians must be aware of potential succinylcholine drug interactions during ECT.
• Careful consideration of concomitant medications, especially psychotropics and chemotherapy agents, is crucial.
• Proactive management strategies and preparedness for complications are essential for patient safety in ECT.